Clinical Trials Logo
  1. Home
  2. Peritoneal Metastases
  3. NCT05676372
  4. Details
NCT05676372 Clinical Trial

Single-Cell Transcriptomics of the Peritoneal Microenvironment of Colorectal PC

Peritoneal Metastases Clinical Trial

— SingleCell  

Official title:
The Role of the Peritoneal Microenvironment in the Pathogenesis of Colorectal Peritoneal Carcinomatosis: Single-cell Transcriptomics

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT05676372
Other study ID # BC-6978
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date June 16, 2020
Est. completion date December 31, 2025

Study information
Verified date December 2023
Source University Hospital, Ghent
Contact Wim P Ceelen, MD, PhD
Phone 093326251
Email wim.ceelen@ugent.be
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Single cell transcriptomics of CRC PC samples

Description:

Research methodology Before inclusion of patients, patients will be screened for the presence of hepatitis B, hepatitis C and HIV to ensure researcher safety. During cytoreductive surgery, a total of five samples of tumoral tissue will be acquired. Three of those samples will be utilized for ScRNASeq analysis, and two samples of a macrometastasis will be snap frozen and cryopreserved. Single-cell RNA-Sequencing analysis We will comprehensively catalog the stromal cell types in the microenvironment of colorectal cancer peritoneal metastases utilizing single-cell RNA sequencing (scRNAseq) on three samples (one of which should preferably originate from the omentum majus, to encompass milky spots) acquired from surgical waste material of patients undergoing cytoreductive surgery. After sample prelevation, samples will be transported as soon as possible while cooled and submerged in 10% PBS to the VIB facilities, where single cell suspensions will be made according to standard protocols. After cell selection by FACS (CD45+ and live/dead stain, to ensure a 50/50 mix of immune and stromal cells) and library prep, ScRNASeq will be performed. Single cell sequencing analysis will allow us to identify cell clusters that by usage of marker genes will be assigned to different known cell lineages. After annotation of data, a "landscape" of the composition of the tumor stroma will be acquired.

Recruitment information / eligibility
Status Recruiting
Enrollment 50
Est. completion date December 31, 2025
Est. primary completion date December 31, 2025
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Patients undergoing CRS+HIPEC for PC of colorectal origin Exclusion Criteria: - Previous HIPEC/PIPAC

Study Design

Related Conditions & MeSH terms

Intervention

Procedure:
• CRC+HIPEC
Sample prelevation of cytoreductive surgery

Locations
Country Name City State
Belgium UZ Ghent Ghent Oost-Vlaanderen

Sponsors (2)
Lead Sponsor Collaborator
University Hospital, Ghent Flemish institute of biotechnology (VIB)

Country where clinical trial is conducted

Belgium, 

Outcome
Type Measure Description Time frame Safety issue
Primary Single-cell transcriptomics A transcriptional single-cell RNA seq atlas of gene expression data will be reported 24 months
See also
  Status Clinical Trial Phase
Recruiting NCT03422432 - Prophylactic HIPEC for Colorectal Cancers at High Risk of Developing Peritoneal Metastases N/A
Not yet recruiting NCT06295094 - The Efficacy of PIPAC and Minimally Invasive Radical Resection in High-risk Gastric Cancer Patients. Phase 2
Recruiting NCT05056389 - Normothermic Intraperitoneal Chemotherapy - Long Term in Peritoneal Metastases From Colorectal Cancer (NIPEC-OXA) Phase 1
Withdrawn NCT03682744 - CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC) Phase 1
Recruiting NCT06367270 - The Application of Pressured Intraperitoneal Aerosol Chemotherapy (PIPAC) for Peritoneal Surface Malignancies Phase 2
Recruiting NCT05623787 - Diagnostic Value of Diffusion-weighted Magnetic Resonance in High-risk Colorectal and Appendiceal Neoplasms N/A
Not yet recruiting NCT05095467 - HIPEC-AS in Patients With Peritoneal Metastasis of the Stomach or Esophagogastric Junction Phase 2
Completed NCT04083547 - Circulating Tumour Cells in Patients With Peritoneal Metastases
Recruiting NCT06216561 - Intraperitoneal LSTA1 in CRS-HIPEC Phase 1
Recruiting NCT05277766 - Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer Phase 1
Not yet recruiting NCT05318794 - Neoadjuvant Systemic and Peritoneal Chemotherapy for Advanced Gastric Cancer Phase 2
Completed NCT05665257 - Feasibility of Preoperative Inspiratory Muscle Training for Patients With Peritoneal Metastases N/A
Terminated NCT05581719 - A Phase 1/2a Study Evaluating Allocetra-OTS as Monotherapy or in Combination With Anti-PD-1 Therapy for the Treatment of Advanced Solid Tumor Malignancy Phase 1/Phase 2
Recruiting NCT05379790 - Concomitant Intraperitoneal and Systemic Chemotherapy in Patients With Extensive Peritoneal Carcinomatosis of Gastric Origin Phase 1
Recruiting NCT04956068 - PIPAC for Peritoneal Metastases Phase 1
Recruiting NCT05204173 - Efficacy and Safety of Sintilimab Combined Intraperitoneal and Intravenous Paclitaxel Plus Oral S-1 in Gastric Cancer Patients With Peritoneal Metastasis Phase 2
Recruiting NCT04861558 - Efficacy of Hyperthermic Intraperitoneal Chemotherapy Phase 3
Recruiting NCT05340569 - Diagnostic Value of DWI-MRI for Detection of Peritoneal Metastases in High-risk Pancreatic Ductal Adenocarcinoma. N/A
Recruiting NCT03834272 - Feasibility of the LUM Imaging System for Peritoneal Surface Malignancies Phase 1/Phase 2
Completed NCT03733184 - Development of an IDEAL Framework to Standardise Cytoreductive Surgery for Colorectal Peritoneal Metastases